In UPCI 95-033, only 2 of 6 enrolled participants received scheduled two vaccinations; 4 other participants were withdrawn from the trial because of tumor progression prior to the first vaccination, as it required at least 7 to 8 weeks to generate sufficient numbers of IL-4-transfected vaccine cells (Table 1). This evidence concerns the gene IL4 and neoplasm.